U.S. Professional Services Stock News

NasdaqGS:GH
NasdaqGS:GHHealthcare

What Catalysts Are Changing the Narrative for Guardant Health?

Guardant Health's consensus analyst price target saw only a slight increase in the most recent update, moving from $61.33 to $62.41. This relatively stable price expectation reflects strong revenue momentum and continued leadership in liquid biopsy technology. It also shows tempered optimism following recent clinical data results. Read on to discover what is driving these perspectives and how you can stay informed about evolving developments for Guardant Health moving forward. What Wall...
NasdaqGM:AVDL
NasdaqGM:AVDLPharmaceuticals

Why The Story Around Avadel Pharmaceuticals Is Evolving After Recent Analyst and Market Updates

Avadel Pharmaceuticals recently saw its consensus analyst price target edge up slightly from $20.20 to $20.30, reflecting a largely steady outlook. This minimal change is rooted in a balance between optimism over Lumryz’s commercial momentum and lingering concerns about ongoing competition in the sleep disorder market. Read on to discover how you can stay informed about ongoing shifts in the stock's narrative as new developments unfold. What Wall Street Has Been Saying Analyst commentary on...
NasdaqGS:CLBT
NasdaqGS:CLBTSoftware

How the Narrative Surrounding Cellebrite Is Shifting Amid Federal Delays and Future Catalysts

Cellebrite DI's consensus analyst price target has seen a modest uptick, rising from $22.57 to $23.14 despite several headwinds. While lingering softness in the U.S. federal market and revised revenue estimates have tempered enthusiasm, analysts attribute much of this to deal timing delays rather than a loss of demand. Stay tuned to find out how you can track ongoing developments in Cellebrite DI's evolving story. What Wall Street Has Been Saying Analyst coverage of Cellebrite DI reflects a...
NasdaqGS:PFIS
NasdaqGS:PFISBanks

Exploring 3 Undervalued Small Caps With Insider Buying In The Global Market

As the U.S. stock market experiences a downturn led by declines in tech shares, small-cap stocks present an intriguing opportunity for investors navigating the current economic landscape shaped by recent Federal Reserve rate cuts. In this environment, identifying small-cap companies with strong fundamentals and insider buying can be key to uncovering potential value amidst broader market fluctuations.
NasdaqCM:ASPI
NasdaqCM:ASPIChemicals

September 2025's Top Growth Companies With Insider Influence

In September 2025, U.S. stock markets have experienced a downturn, with major indices like the Dow Jones Industrial Average, S&P 500, and Nasdaq all closing lower due to declines in tech shares following Federal Reserve Chair Jerome Powell's comments on interest rates. Amidst this backdrop of fluctuating market conditions and high valuations, growth companies with significant insider ownership can offer a unique perspective on potential resilience and strategic direction in uncertain times.
NasdaqCM:MVST
NasdaqCM:MVSTMachinery

Spotlight On Top Penny Stocks In September 2025

As of late September 2025, the U.S. stock market has experienced a downturn, with major indices such as the Dow Jones Industrial Average, S&P 500, and Nasdaq closing lower due to declines in tech stocks following comments from Federal Reserve Chair Jerome Powell. Amidst these broader market movements, investors often look for opportunities that offer potential growth at lower price points. Penny stocks—though an older term—still represent a compelling investment area by highlighting smaller...